Published by Irving Nachamkin, DrPH, MPH, D(ABMM), FAAM, FIDSA, on April 08, 2020
It was inevitable that companies would start pushing out tests for measuring antibodies to SARS-CoV-2, but there has been a lot of discussion in our professional circles about the status of these assays and whether there is value to use them in the current situation.
Read more
Published by Irving Nachamkin, DrPH, MPH, D(ABMM), FAAM, FIDSA, on May 09, 2016
The Zika outbreak provides a good example of why the FDA’s position on LDTs is misguided.
Read more
Published by Irving Nachamkin, DrPH, MPH, D(ABMM), FAAM, FIDSA, on December 22, 2015
We need congressional action to modernize CLIA regulations that ensure the quality of Lab Developed Tests (LDTs), rather than having the FDA impose new and unrealistic regulations on top of CLIA requirements.
Read more
Published by Irving Nachamkin, DrPH, MPH, D(ABMM), FAAM, FIDSA, on September 29, 2015
Reducing unnecessary lab tests needs to be part of the routine thought process for every patient by every provider of care.
Read more
Published by Irving Nachamkin, DrPH, MPH, D(ABMM), FAAM, FIDSA, on April 17, 2015
April is an exciting time of year for all who work in Pathology and Laboratory Medicine. We get to enjoy longer daylight, warmer temperatures, but, especially, we celebrate our own during Medical Laboratory Professionals Week, aka Lab Week.
Read more
Published by Irving Nachamkin, DrPH, MPH, on January 15, 2015
On a recent morning, I asked a few non-lab staff whether they knew what goes on in “The Lab” and even where “The Lab” was located. Many of the physician providers I have come to know over the years don’t even know the answer.
Read more